Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 149Rituximab 104Peripheral Blood Stem Cell Transplantation 101fludarabine phosphate 100Filgrastim 72Mycophenolic Acid 67Cyclosporine 59Radiotherapy 58Whole-Body Irradiation 57Etoposide 55Tacrolimus 51Busulfan 50Antilymphocyte Serum 43Melphalan 41Methotrexate 37Cytarabine 27Cord Blood Stem Cell Transplantation 26fludarabine 25Bortezomib 24Methylprednisolone 23Carmustine 22sargramostim 21Flow Cytometry 19Dexamethasone 19Lenalidomide 18Granulocyte Colony-Stimulating Factor 18Vincristine 17Prednisone 17Bendamustine Hydrochloride 17aldesleukin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × tafasitamab × Other hematologic neoplasm × Clear all
NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Case Comprehensive Cancer Center

Phase 1 Not yet recruiting
15 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡